Anavex Life Sciences Corp (AVXL)

[nidan7500]

Nice work PW, as you point out 115 years is a long time for any science to be continuously wrong. That fact alone is mind blowing, IMO.

On Nov. 3, 1906, German psychiatrist Alois Alzheimer presented the clinical features of Auguste Deter — the first patient diagnosed with the disease — together with the neuropathological features that included brain shrinkage and the presence of a protein found between brain cells (amyloid plaques) and the Tau protein identified within the brain cell.

Today, more than 115 years later, Alzheimer’s is a major health problem globally, and the amyloid hypothesis — that amyloid accumulation causes dementia — dominates the research community. This hypothesis has guided drug development, and pharmaceutical companies saw a huge opportunity. Lecanemab is the first drug that lowers brain amyloid levels and ostensibly slows progression. That being said, that proof of principle is tenuous in this case. The Lancet editorial appropriately states, “Whether lecanemab is the game changer that some have suggested remains to be seen.”

[Published in Chicago Tribune 1/27/2023]

The U.S. Food and Drug Administration recently approved a new drug for the treatment of Alzheimer’s disease. AP 2020

By Anand Kumar